Table 3 Summary of the antimicrobial susceptibility testing results of AXDX, after adjudication
Antimicrobial | EA | CA | VME | ME | mE | S | I | R | ||
|---|---|---|---|---|---|---|---|---|---|---|
No. results/total | % | No. results/total | % | |||||||
Amikacin | 82/82 | 100% | 84/84 | 100% | 0 | 0 | 0 | 77 | 0 | 7 |
Ampicillin-Sulbactam | 57/62 | 91.9% | 48/62 | 77.4% | 0 | 0 | 14 | 30 | 7 | 25 |
Aztreonam | 71/74 | 95.9% | 72/75 | 96% | 0 | 0 | 3 | 54 | 1 | 20 |
Cefepime | 79/82 | 96.3% | 79/83 | 95.2% | 0 | 0 | 4 | 60 | 2 | 21 |
Ceftriaxone | 74/74 | 100% | 71/75 | 94.7% | 0 | 0 | 4 | 52 | 1 | 22 |
Ciprofloxacin | 79/83 | 95.2% | 84/84 | 100% | 0 | 0 | 0 | 48 | 0 | 36 |
Ertapenem | 72/73 | 98.6% | 72/73 | 98.6% | 0 | 0 | 1 | 65 | 0 | 8 |
Gentamicin | 80/83 | 96.4% | 84/84 | 100% | 0 | 0 | 0 | 66 | 0 | 18 |
Meropenem | 79/83 | 95.2% | 83/85 | 97.6% | 0 | 0 | 2 | 70 | 1 | 14 |
Piperacillin-Tazobactam | 63/68 | 92.6% | 70/75 | 93.3% | 0 | 0 | 5 | 55 | 3 | 17 |
Tobramycin | 78/83 | 94% | 77/84 | 91.7% | 0 | 0 | 7 | 62 | 5 | 17 |
Overall | 814/847 | 96.1% | 824/864 | 95.4% | 0 | 0 | 40 | 639 | 20 | 205 |